Raphael Pharmaceutical (RAPH) Total Current Liabilities (2020 - 2025)

Raphael Pharmaceutical has disclosed Total Current Liabilities across 6 years of filings, most recently posting $1.5 million for Q4 2025.

• Total Current Liabilities for Q4 2025 came in at $1.5 million, up 93.24% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.5 million (up 93.24% YoY), and the FY2025 annual result was $1.5 million, up 93.24% from the prior year.
• Total Current Liabilities came in at $1.5 million for Q4 2025 at Raphael Pharmaceutical, up from $1.3 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $1.5 million in Q4 2025 to a low of $77000.0 in Q1 2022.
• The 5-year median for Total Current Liabilities is $356000.0 (2021), against an average of $498166.7.
• Across the five-year window, Total Current Liabilities plunged 41.85% in 2023 and soared 482.58% in 2024, its largest moves.
• Raphael Pharmaceutical's Total Current Liabilities stood at $294000.0 in 2021, then dropped by 22.79% to $227000.0 in 2022, then plunged by 41.85% to $132000.0 in 2023, then jumped by 482.58% to $769000.0 in 2024, then jumped by 93.24% to $1.5 million in 2025.
• The last three Total Current Liabilities figures came in at $1.5 million (Q4 2025), $1.3 million (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.